1 | CYP2C9
|
| Massively parallel characterization of CYP2C9 variant enzyme activity and abundance
|
| Amorosi CJ, Chiasson MA, McDonald MG, Wong LH, Sitko KA, Boyle G, Kowalski JP, Rettie AE, Fowler DM, Dunham MJ.
|
| Am J Hum Genet. Sep 2;108(9):1735-1751. doi: 10.1016/j.ajhg.2021.07.001. Epub 2021 Jul 26. 2021
|
2 | CYP2C9
|
| Impact of CYP2C9-Interacting Drugs on Warfarin Pharmacogenomics.
|
| Agrawal S, Heiss MS, Fenter RB, Abramova TV, Perera MA, Pacheco JA, Smith ME, Rasmussen-Torvik LJ, George AL Jr.
|
| Clin Transl Sci. Sep;13(5):941-949. doi: 10.1111/cts.12781. Epub 2020 Apr 9. 2020
|
3 | CYP2C9
|
| Estimation of Interindividual Variability of Pharmacokinetics of CYP2C9 Substrates in Humans
|
| Chiba K, Shimizu K, Kato M, Miyazaki T, Nishibayashi T, Terada K, Sugiyama Y.
|
| J Pharm Sci. Sep;106(9):2695-2703. doi: 10.1016/j.xphs.2017.04.021. Epub 2017 Apr 21. 2017
|
4 | CYP2C19, CYP2C8, CYP2C9
|
| Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants
|
| Hiratsuka M.
|
| Biol Pharm Bull. 39(11):1748-1759. doi: 10.1248/bpb.b16-00605. 2016
|
5 | CYP2C19, CYP2C9
|
| Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs
|
| Hirota T, Eguchi S, Ieiri I.
|
| Drug Metab Pharmacokinet. 28(1):28-37. doi: 10.2133/dmpk.dmpk-12-rv-085. Epub 2012 Nov 20. 2013
|
6 | CYP2C9, VKORC1
|
| Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.
|
| Jorgensen AL, FitzGerald RJ, Oyee J, Pirmohamed M, Williamson PR.
|
| PLoS One 7(8):e44064. doi: 10.1371/journal.pone.0044064. Epub 2012 Aug 29. Review.
2012
|
7 | CYP2C9, CYP4F2, VKORC1
|
| A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
|
| Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P.
|
| PLoS Genet 5(3):e1000433. Epub 2009 Mar 20.
2009
|
8 | CYP2C9, VKORC1
|
| Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.
|
| Scott SA, Edelmann L, Kornreich R, Desnick RJ.
|
| Am J Hum Genet 82(2):495-500. Epub 2008 Jan 17. 2008
|
9 | CYP2C9, VKORC1
|
| Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation.
|
| Li T, Lange LA, Li X, Susswein L, Bryant B, Malone R, Lange EM, Huang TY, Stafford DW, Evans JP.
|
| J Med Genet 43(9):740-4. Epub 2006 Apr 12. 2006
|
10 | CYP2C9
|
| Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.
|
| Schwarz UI.
|
| Eur J Clin Invest 33 Suppl 2:23-30. Review. 2003
|
11 | CYP2B6, CYP2C9, CYP3A4
|
| Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes.
|
| Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ.
|
| J Biol Chem 277(28):25125-32. 2002
|
12 | CYP2C18, CYP2C19, CYP2C8, CYP2C9
|
| The human CYP2C locus: a prototype for intergenic and exon repetition splicing events.
|
| Finta C, Zaphiropoulos PG.
|
| Genomics 63(3):433-438. 2000
|
13 | CYP2C9
|
| Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.
|
| Miners JO, Birkett DJ.
|
| Br J Clin Pharmacol 45(6):525-38. Review. 1998
|
14 | CYP24A1, CYP26A1, CYP27A1, CYP27B1, CYP2A, CYP2@, CYP2A13, CYP2A6, CYP2A7, CYP2A7P1, CYP2B, CYP2B6, CYP2B7P1, CYP2C@, CYP2C18, CYP2C19, CYP2C8, CYP2C9, CYP2D@, CYP2D6, CYP2D7P1, CYP2D7P2, CYP2D8P1, CYP2D8P2, CYP2E1, CYP2F1, CYP2F1P, CYP2G1P, CYP2G2P, CYP2J2, CYP2S1, CYP2T2P, CYP2T3P
|
| Molecular genetics of the human cytochrome P450 monooxygenase superfamily.
|
| Smith G, Stubbins MJ, Harries LW, Wolf CR.
|
| Xenobiotica 28(12):1129-65. Review. No abstract available. 1998
|
15 | CYP2C18, CYP2C19, CYP2C8, CYP2C9
|
| A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24.
|
| Gray IC, Nobile C, Muresu R, Ford S, Spurr NK.
|
| Genomics 28(2):328-32. 1995
|
16 | CYP2C18, CYP2C19, CYP2C8, CYP2C9
|
| Fluorescence in situ hybridization analysis of chromosomal localization of three human cytochrome P450 2C genes (CYP2C8, 2C9, and 2C10) at 10q24.1.
|
| Inoue K, et al.
|
| Jpn J Hum Genet 39 : 337-343. 1994
|
17 | CYP2C18, CYP2C9
|
| Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18.
|
| de Morais SM, Schweikl H, Blaisdell J, Goldstein JA.
|
| Biochem Biophys Res Commun 194(1):194-201. 1993
|
18 | CYP2C9
|
| Six-base deletion occurring in messages of human cytochrome P-450 in the CYP2C subfamily results in reduction of tolbutamide hydroxylase activity.
|
| Ohgiya S, Komori M, Ohi H, Shiramatsu K, Shinriki N, Kamataki T.
|
| Biochem Int 27(6):1073-81. 1992
|
19 | CYP2C9, CYP2C19
|
| Cloning and expression of complementary DNAs for multiple members of the human cytochromosome P450IIC subfamily.
|
| Romkes M, et al.
|
| Biochemistry 30 : 3247-3255. 1991
|
20 | CYP2C9
|
| Human cytochrome P-450 PB-I : a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10.
|
| Meehan RR, Gosden JR, Rout D, Hastie ND, Friedberg T, Adesnik M, Buckland R, van Heyningen V, Fletcher J, Spurr NK, et al.
|
| Am J Hum Genet 42 : 26-37. 1988
|